肿瘤细胞治疗研究
FRONTIER PAPERS
Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication.
嵌合抗原受体（CAR）-T 细胞疗法在血液系统恶性肿瘤中的成功尚未转化至实体瘤，主要原因是 T 细胞浸润不足以及驱动 T 细胞耗竭的免疫抑制性肿瘤微环境。
Targeting TGFβ docking receptor glycoprotein A repetitions predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat gliob
GARP-LTGF 在 GBM 的发生和预后中发挥关键作用，靶向 GARP 的 CAR-T 治疗在小鼠原位 GBM 模型中显示出有前景的疗效和安全性。
αvβ3 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative
本文测试了两种版本的v 3 CAR-T构建体，分别含有CD28或4-1BB共刺激结构域。
Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors.
我们报道了一种结合表观遗传和BCL-XL抑制剂与ICB的新型方案，该方案在多种实体瘤的临床前模型中产生了强效的抗肿瘤反应。
Go to the scene: T(H)9 cells superior migration ability to the lungs explains their exceptional anticancer efficacy.
过去13年的这些发现支持了TH9细胞在癌症过继治疗中的临床评估。
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.
嵌合抗原受体工程化 NK 细胞在过继性肿瘤免疫治疗中展现出前景。
Bacterial RNA downregulates MHC-I in tumor cell lines, promoting NK response and delaying tumor growth.
我们建立的MHC-I下调模型（通过bacRNA或合成hTLR8激动剂）可作为促进抗肿瘤反应的治疗策略。
Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, an
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other soli
这些数据表明WT1-mRNA/DC疫苗接种在晚期实体瘤患者中是可行的、安全的且具有免疫原性，并显示出临床活性，提示其有潜力帮助改善患者的生存。
Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity.
这些结果提示达沙替尼可提高γδ T细胞的产量和功能，为优化基于γδ T细胞的过继治疗（尤其是实体瘤）提供了一种实用且可转化的策略。试验注册：试验编号：CMUH111-REC3-185。
MEMBER ACCOUNT
登录成功会直接打开下一页。
